Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087620 · ClinicalTrials.gov registry record · Phase 4
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 4
- Development phase
NCT00087620 is a Phase 4 study that was terminated before completion, run by Hoffmann-La Roche.
The verdict
NCT00087620, a Phase 4 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 4
- Development phase
Study Summary
To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).
Interventions
- DRUG XELODA [capecitabine]
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-09 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087620
The ClinicalTrials.gov registry entry for NCT00087620 describes a study currently listed as terminated, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XELODA [capecitabine] is the first listed.
NCT00087620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087620 about?
NCT00087620 is a clinical study titled "A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer". To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).
What is the current status of trial NCT00087620?
This trial is currently terminated. It is a Phase 4 study. The study started on 2004-09. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00087620?
The interventions under investigation include: XELODA [capecitabine] (DRUG).
Who is sponsoring clinical trial NCT00087620?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.